Pierre-RÃ©gis Burgel

List of Publications by Year
in descending order

166 papers	7,662 citations	53794 45 h-index	60623 81 g-index
176 all docs	176 docs citations	176 times ranked	9700 citing authors

#	Article	IF	Citations
1	Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 155-159.	0.7	6
2	Impact of a high emergency lung transplantation programme for cystic fibrosis in France: insight from a comparison with Canada. European Respiratory Journal, 2022, 59, 2100014.	6.7	7
3	Cystic Fibrosis in 2021: â€œThe Times They Are A-Changinâ€• Archivos De Bronconeumologia, 2022, 58, 536-538.	0.8	1
4	Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge. Journal of Cystic Fibrosis, 2022, 21, 691-706.	0.7	8
5	Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging. European Respiratory Journal, 2022, , 2200022.	6.7	0
6	Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 489-496.	0.7	38
7	Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 584-586.	5.6	26
8	Change in Lung Function after Initiation of Elexacaftorâ€“Tezacaftorâ€“Ivacaftor: Do Not Forget Anatomy!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1365-1366.	5.6	1
9	Tobramycin safety and efficacy review article. Respiratory Medicine, 2022, 195, 106778.	2.9	5
10	Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. Respiratory Medicine and Research, 2022, 81, 100889.	0.6	0
11	Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers. Journal of Clinical and Translational Endocrinology, 2022, 28, 100298.	1.4	2
12	Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis. Clinical Infectious Diseases, 2022, 75, 2135-2144.	5.8	9
13	People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study. ERJ Open Research, 2022, 8, 00686-2021.	2.6	3
14	Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. European Respiratory Review, 2022, 31, 210259.	7.1	10
15	CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells, 2022, 11, 1769.	4.1	17
16	No patient left behind! Therapeutic options for cystic fibrosis patients living with lung transplantation. Journal of Cystic Fibrosis, 2022, , .	0.7	0
17	Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respiratory Medicine, 2022, 200, 106921.	2.9	14
18	Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Journal of Cystic Fibrosis, 2022, 21, e221-e231.	0.7	15

#	Article	IF	Citations
19	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227.	0.7	24
20	Effective control ofStaphylococcus aureuslung infection despite tertiary lymphoid structure disorganisation. European Respiratory Journal, 2021, 57, 2000768.	6.7	6
21	Mucus Plugs in Medium-sized Airways: A Novel Imaging Biomarker for Phenotyping Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 932-934.	5.6	2
22	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. Journal of Cystic Fibrosis, 2021, 20, 25-30.	0.7	62
23	â€œIl faut continuer Ã poser des questionsâ€•patient reported outcome measures in cystic fibrosis: An anthropological perspective. Journal of Cystic Fibrosis, 2021, 20, e108-e113.	0.7	4
24	Rapid Improvement after Starting Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73.	5.6	139
25	Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. International Journal of COPD, 2021, Volume 16, 321-332.	2.3	18
26	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653.	6.7	16
27	Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD. International Journal of COPD, 2021, Volume 16, 1275-1284.	2.3	8
28	Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. Journal of Cystic Fibrosis, 2021, 20, 566-577.	0.7	34
29	COVID-19 vaccine prioritisation for people with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 715-716.	0.7	5
30	Reply to Kuek etÂal.: Optimism with Caution: Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 372-374.	5.6	10
31	COVID-19 outcomes in people with cystic fibrosis. Current Opinion in Pulmonary Medicine, 2021, 27, 538-543.	2.6	13
32	Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. International Journal of COPD, 2021, Volume 16, 2363-2373.	2.3	14
33	Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries. European Respiratory Journal, 2021, 58, 2101487.	6.7	2
34	Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Respiratory Medicine and Research, 2021, 80, 100829.	0.6	16
35	Management of early infection with Pseudomonas aeruginosa in adults with bronchiectasis: A survey of French pulmonologist's practices. Respiratory Medicine and Research, 2021, 80, 100859.	0.6	0
36	Topological data analysis reveals genotypeâ€“phenotype relationships in primary ciliary dyskinesia. European Respiratory Journal, 2021, 58, 2002359.	6.7	49

#	Article	IF	Citations
37	Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis. European Respiratory Journal, 2021, , 2101344.	6.7	19
38	Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?. European Respiratory Journal, 2021, , 2102924.	6.7	0
39	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	10.7	573
40	Real-Life Safety and Effectiveness of Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197.	5.6	95
41	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
42	Arpin is critical for phagocytosis in macrophages and is targeted by human rhinovirus. EMBO Reports, 2020, 21, e47963.	4.5	17
43	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	7.1	82
44	First Wave of COVID-19 in French Patients with Cystic Fibrosis. Journal of Clinical Medicine, 2020, 9, 3624.	2.4	33
45	Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?. European Respiratory Journal, 2020, 56, 2002645.	6.7	5
46	Lung immunoglobulin A immunity dysregulation in cystic fibrosis. EBioMedicine, 2020, 60, 102974.	6.1	22
47	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020.	2.6	10
48	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.7	74
49	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 355-358.	0.7	113
50	Airway mucus accumulation in COPD: the cholinergic paradox!. European Respiratory Journal, 2020, 55, 1902473.	6.7	2
51	â€œCanâ€™t Stop the Feelingâ€: Symptoms as the Key to Trial Success in Bronchiectasis?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1461-1462.	5.6	2
52	Validation of short- and long-term demographic forecasts using the Canadian Cystic Fibrosis Registry. European Respiratory Journal, 2020, 55, 1901667.	6.7	2
53	Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A metaâ€analysis. Pediatric Pulmonology, 2020, 55, 2653-2661.	2.0	12
54	Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study. BMJ Open, 2020, 10, e035811.	1.9	5

#	Article	IF	Citations
55	Impact of COVID-19 on people with cystic fibrosis. Lancet Respiratory Medicine,the, 2020, 8, e35-e36.	10.7	114
56	Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 778-781.	1.8	24
57	Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores. Radiology: Cardiothoracic Imaging, 2020, 2, e200022.	2.5	4
58	Are there specific clinical characteristics associated with physicianâ€™s treatment choices in COPD?. Respiratory Research, 2019, 20, 189.	3.6	5
59	Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities . International Journal of COPD, 2019, Volume 14, 1399-1410.	2.3	13
60	Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulmonary Medicine, 2019, 19, 127.	2.0	15
61	Respiratory Medicine and Research: The new English-language journal of the SociÃ©tÃ© de pneumologie de langue franÃ§aise!. Respiratory Medicine and Research, 2019, 75, A1-A2.	0.6	0
62	Relationship between gender and survival in a real-life cohort of patients with COPD. Respiratory Research, 2019, 20, 191.	3.6	14
63	Do Cough and Sputum Production Predict COPD Exacerbations?. Chest, 2019, 156, 641-642.	0.8	6
64	Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death. European Respiratory Journal, 2019, 53, 1801943.	6.7	11
65	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17.	1.6	7
66	Artificial intelligence outperforms pulmonologists in the interpretation ofÂpulmonary function tests. European Respiratory Journal, 2019, 53, 1801660.	6.7	102
67	Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis registry. Journal of Cystic Fibrosis, 2019, 18, 396-398.	0.7	11
68	Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 23-38.	2.5	13
69	Reply to Polverino: Deconvoluting Chronic Obstructive Pulmonary Disease: Are B Cells the Frontrunners?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1171-1172.	5.6	0
70	Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 592-602.	5.6	40
71	PP128 Quantifying The Relative Importance Of Chronic Obstructive Pulmonary Disease Symptoms To Patients. International Journal of Technology Assessment in Health Care, 2019, 35, 61-61.	0.5	0
72	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 928-940.	5.6	62

#	Article	IF	Citations
73	On Don Quixote and pink puffers: multi-organ loss of tissue COPD. European Respiratory Journal, 2018, 51, 1702560.	6.7	2
74	Blood eosinophil counts as a guide for COPD treatment strategies. Lancet Respiratory Medicine,the, 2018, 6, 78-80.	10.7	4
75	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33.	5.5	21
76	Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis. Journal of Clinical Pathology, 2018, 71, 752-753.	2.0	4
77	Automated computed tomographic scoring of lung disease in adults with primary ciliary dyskinesia. BMC Pulmonary Medicine, 2018, 18, 194.	2.0	10
78	Cured bronchi! Extending the use of nebulised hypertonic saline outside of cystic fibrosis?. European Respiratory Journal, 2018, 51, 1800755.	6.7	0
79	An attempt at modeling COPD epidemiological trends in France. Respiratory Research, 2018, 19, 130.	3.6	13
80	Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis. Mediators of Inflammation, 2018, 2018, 1-3.	3.0	4
81	A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre. Journal of Cystic Fibrosis, 2018, 17, 636-642.	0.7	4
82	Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs. Methods in Molecular Biology, 2018, 1845, 223-239.	0.9	10
83	An automated computed tomography score for the cystic fibrosis lung. European Radiology, 2018, 28, 5111-5120.	4.5	16
84	Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia. Thorax, 2017, 72, 154-160.	5.6	77
85	Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. European Respiratory Journal, 2017, 49, 1601873.	6.7	38
86	The changing epidemiology and demography of cystic fibrosis. Presse Medicale, 2017, 46, e87-e95.	1.9	60
87	Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. Journal of Cystic Fibrosis, 2017, 16, 388-391.	0.7	81
88	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 139-149.	5.6	68
89	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	6.7	53
90	A first step to STOP cystic fibrosis exacerbations. Journal of Cystic Fibrosis, 2017, 16, 529-531.	0.7	7

#	Article	IF	Citations
91	Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis. European Respiratory Journal, 2017, 50, 1700763.	6.7	15
92	Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2017, 17, 25.	2.0	9
93	Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatric Pulmonology, 2017, 52, 190-197.	2.0	33
94	Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. Journal of Cystic Fibrosis, 2017, 16, 85-88.	0.7	21
95	Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. International Journal of COPD, 2017, Volume 12, 1819-1824.	2.3	81
96	Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 243.	3.9	16
97	Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infection and Drug Resistance, 2016, Volume 9, 229-238.	2.7	53
98	Impact of current cough on health-related quality of life in patients with COPD. International Journal of COPD, 2016, Volume 11, 2091-2097.	2.3	43
99	Exacerbations of COPD. International Journal of COPD, 2016, 11 Spec Iss, 21.	2.3	79
100	Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. European Respiratory Journal, 2016, 48, 249-252.	6.7	30
101	Renin-associated hypertension after bronchial artery embolization in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 213-215.	0.7	4
102	CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?. Pancreatology, 2016, 16, 515-522.	1.1	6
103	Toward Personalized Prescription of Systemic Steroids for Patients Hospitalized With COPD Exacerbations. Chest, 2016, 150, 268-269.	0.8	2
104	DCTN4 as a modifier of chronicPseudomonas aeruginosainfection in cystic fibrosis. Clinical Respiratory Journal, 2016, 10, 777-783.	1.6	10
105	Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. Journal of Cystic Fibrosis, 2016, 15, 204-212.	0.7	76
106	Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution inPseudomonas aeruginosaInfection. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 740-750.	2.9	20
107	Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. European Respiratory Journal, 2016, 47, 420-428.	6.7	102
108	Modeling future COPD epidemiology. , 2016, , .		0

#	Article	IF	Citations
109	Complications of Peripherally Inserted Central Catheters in Adults with Cystic Fibrosis or Bronchiectasis. Journal of Vascular Access, 2015, 16, 245-249.	0.9	13
110	Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1663.	2.3	70
111	Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis, 2015, 14, 594-599.	0.7	37
112	Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment. European Respiratory Journal, 2015, 45, 260-262.	6.7	4
113	United Airway Diseases. Should We Add Upper Airway Inflammatory Disorders to the List of Chronic Obstructive Pulmonary Disease Comorbidities?. Annals of the American Thoracic Society, 2015, 12, 968-970.	3.2	5
114	Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 2015, 46, 133-141.	6.7	238
115	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	5.6	166
116	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	6.7	138
117	Hostâ€“microbe interactions in distal airways: relevance to chronic airway diseases. European Respiratory Review, 2015, 24, 78-91.	7.1	35
118	Identification of Clinical Phenotypes Using Cluster Analyses in COPD Patients with Multiple Comorbidities. BioMed Research International, 2014, 2014, 1-9.	1.9	55
119	Association of chronic nasal symptoms with dyspnoea and qualityâ€ofâ€life impairment in chronic obstructive pulmonary disease. Respirology, 2014, 19, 346-352.	2.3	15
120	Monitoring disease progression in COPD patients: one step beyond!. European Respiratory Journal, 2014, 43, 665-667.	6.7	0
121	Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?. European Respiratory Journal, 2014, 43, 1201-1203.	6.7	31
122	Impact of gender on COPD expression in a real-life cohort. Respiratory Research, 2014, 15, 20.	3.6	35
123	Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nature Communications, 2014, 5, 5105.	12.8	110
124	Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respiratory Research, 2014, 15, 64.	3.6	11
125	p.Arg75Gln, a CFTR variant involved in the risk of CFTR-related disorders?. Journal of Human Genetics, 2014, 59, 206-210.	2.3	11
126	Targeting Mucus Hypersecretion: New Therapeutic Opportunities for COPD?. Drugs, 2014, 74, 1073-1089.	10.9	40

#	Article	IF	Citations
127	Multimorbidity in Elderly Patients with Chronic Obstructive Pulmonary Disease: Stop Smoking! Go Exercise?. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 7-8.	5.6	4
128	Prognostic value of six minute walk test in cystic fibrosis adults. Respiratory Medicine, 2013, 107, 1881-1887.	2.9	51
129	Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 497-503.	0.7	103
130	Impact of comorbidities on COPD-specific health-related quality of life. Respiratory Medicine, 2013, 107, 233-241.	2.9	103
131	Chronic Cough in Chronic Obstructive Pulmonary Disease: Time for Listening?. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 902-904.	5.6	9
132	CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. European Respiratory Journal, 2013, 42, 1553-1562.	6.7	19
133	Dysfunctional lung anatomy and small airways degeneration in COPD. International Journal of COPD, 2013, 8, 7.	2.3	17
134	Chronic cough and sputum production: a clinical COPD phenotype?: Table 1â€“. European Respiratory Journal, 2012, 40, 4-6.	6.7	33
135	Pulmonary Acceleration Time to Optimize the Timing of Lung Transplant in Cystic Fibrosis. Pulmonary Circulation, 2012, 2, 75-83.	1.7	13
136	Targeting cytosolic proliferating cell nuclear antigen in neutrophil-dominated inflammation. Frontiers in Immunology, 2012, 3, 311.	4.8	31
137	Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 936-937.	5.6	4
138	Bronchial rupture related to endobronchial stenting in relapsing polychondritis. European Respiratory Review, 2012, 21, 367-369.	7.1	14
139	Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. Archives of Disease in Childhood, 2012, 97, 960-966.	1.9	47
140	Clinical COPD phenotypes identified by cluster analysis: validation with mortality. European Respiratory Journal, 2012, 40, 495-496.	6.7	38
141	High Prevalence of Azole-Resistant Aspergillus fumigatus in Adults with Cystic Fibrosis Exposed to Itraconazole. Antimicrobial Agents and Chemotherapy, 2012, 56, 869-874.	3.2	164
142	Employment and work disability in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 137-143.	0.7	30
143	Association between occupational exposure and the clinical characteristics of COPD. BMC Public Health, 2012, 12, 302.	2.9	22
144	Everolimus-related organizing pneumonia: a report establishing causality. Investigational New Drugs, 2012, 30, 1244-1247.	2.6	7

#	Article	IF	Citations
145	Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality. PLoS ONE, 2012, 7, e51048.	2.5	104
146	Liver disease in adult patients with cystic fibrosis: A frequent and independent prognostic factor associated with death or lung transplantation. Journal of Hepatology, 2011, 55, 1377-1382.	3.7	64
147	Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2011, 208, 1635-1648.	8.5	739
148	Mediastinal Tuberculosis in an Adult Patient with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 750-751.	3.9	8
149	Cystic Fibrosis Transmembrane Conductance Regulator Channel Dysfunction in Nonâ€“Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1078-1084.	5.6	85
150	Î²2-Agonist modulates epithelial gene expression involved in the T- and B-cell chemotaxis and induces airway sensitization in human isolated bronchi. Pharmacological Research, 2010, 61, 121-128.	7.1	12
151	Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Medical Mycology, 2010, 48, S32-S36.	0.7	114
152	Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects. Chest, 2009, 135, 975-982.	0.8	299
153	Heme Oxygenase-1 Prevents Airway Mucus Hypersecretion Induced by Cigarette Smoke in Rodents and Humans. American Journal of Pathology, 2008, 173, 981-992.	3.8	40
154	Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. Respiratory Care, 2008, 53, 1482-9.	1.6	27
155	A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax, 2007, 62, 153-161.	5.6	125
156	MUC5AC, a Gel-Forming Mucin Accumulating in Gallstone Disease, Is Overproduced via an Epidermal Growth Factor Receptor Pathway in the Human Gallbladder. American Journal of Pathology, 2006, 169, 2031-2041.	3.8	47
157	Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respiratory Research, 2006, 7, 14.	3.6	43
158	One-year Outcome after Severe Pulmonary Exacerbation in Adults with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 158-164.	5.6	112
159	IL-13-induced Clara cell secretory protein expression in airway epithelium: role of EGFR signaling pathway. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L67-L75.	2.9	40
160	Mucus and Mucin-Secreting Cells. , 2002, , 155-163.		2
161	The role of epidermal growth factor in mucus production. Current Opinion in Pharmacology, 2001, 1, 254-258.	3.5	74
162	Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L165-L172.	2.9	230

#	Article	IF	Citations
163	IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L134-L140.	2.9	217
164	Human Eosinophils Induce Mucin Production in Airway Epithelial Cells Via Epidermal Growth Factor Receptor Activation. Journal of Immunology, 2001, 167, 5948-5954.	0.8	132
165	Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. Journal of Allergy and Clinical Immunology, 2000, 105, 739-745.	2.9	40
166	Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps. Journal of Allergy and Clinical Immunology, 2000, 106, 705-712.	2.9	69